Hadassah

Oral Insulin Pill, Based on Hadassah Medical Center Research, Cleared by FDA for Clinical Trial in US

Tuesday, May 21 2013

The oral insulin pill (ORMD-0801), based on over 30 years of research by Hadassah Medical Center scientists, and developed by the Israeli company, Oramed Pharmaceuticals Inc., has been cleared by the United States Food and Drug Administration (FDA) for Phase 2 clinical trials in the US.

The orally ingestible capsule is indicated for those with early stage type two diabetes, when it can slow the rate of disease progression by providing additional insulin to the body and allowing the pancreas a respite. The pill delivery system has the advantage of mimicking insulin's natural location and gradients in the body by first passing through the liver before entering the bloodstream. "We are very pleased to have the FDA clearance to proceed," stated Nadav Kidron, Chief Executive Officer of Oramed. "The upcoming trial is a major milestone for Oramed and we look forward to continuing to progress ORMD-0801's clinical development in the US."

Read more about the insulin pill from Hadassah International>>

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More